The nation’s three dominant drug distributors and a big drugmaker have reached a $260 million deal to settle an opioid crisis lawsuit just as the first federal trial over the crisis was due to begin.
Purdue’s promotions exaggerated the drug’s safety and risks of addiction, leaning heavily on one sentence used by sales reps to market the drug to doctors.
Recently unsealed documents shed light on how the maker of OxyContin seems to have relied more on focus groups than on scientific studies to create an aggressive and misleading marketing campaign that helped fuel the national opioid epidemic.
